Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.13 is 60% below its 2-year average of 0.33, near the low end of its 2-year range (0.00–0.49).
As of the fiscal period ended Tuesday, March 31, 2026. 62.46% below its 12-month average of 0.35.
Reported quarterly debt to equity ratio; no daily interpolation. Q4 FY2026 (2026-03-31): 0.13.
DEBT TO EQUITY RATIO
0.13
DEBT TO EQUITY RATIO AVG TTM
0.35
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-62.46%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 579 covered companies
CURRENT VS SECTOR MEDIAN
+0.99%
vs the sector median at left
Cellyan Biotechnology Co., Ltd
Market Cap
$1.10M
Debt to Equity Ratio
0.13
TTM Avg
0.35
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.07M
Debt to Equity Ratio
0.14
TTM Avg
0.76
3Y Avg
0.50
5Y Avg
0.30
Market Cap
$1.03M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$1.24M
Debt to Equity Ratio
N/A
TTM Avg
0.05
3Y Avg
0.05
5Y Avg
0.05
Market Cap
$870069.00
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$862314.00
Debt to Equity Ratio
N/A
TTM Avg
0.01
3Y Avg
0.08
5Y Avg
0.06
Market Cap
$856468.00
Debt to Equity Ratio
0.00
TTM Avg
0.07
3Y Avg
0.05
5Y Avg
0.04
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellyan Biotechnology Co., Ltd (HKPD) | $1.10M | 0.13 | 0.35 | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.07M | 0.14 | 0.76 | 0.50 | 0.30 |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | 0.00 | 0.00 | 0.00 | 0.00 |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.24M | N/A | 0.05 | 0.05 | 0.05 |
| IM Cannabis Corp. (IMCC)vs › | $1.16M | N/A | 2.19 | 1.26 | 0.86 |
| Bone Biologics Corporation (BBLG)vs › | $870069.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| GlucoTrack, Inc. (GCTK)vs › | $862314.00 | N/A | 0.01 | 0.08 | 0.06 |
| Decoy Therapeutics Inc. (DCOY)vs › | $856468.00 | 0.00 | 0.07 | 0.05 | 0.04 |
| Genprex, Inc. (GNPX)vs › | $1.36M | 0.00 | 0.00 | 0.00 | 0.00 |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $832531.00 | 0.01 | 0.03 | 0.06 | 0.04 |
Debt/Equity
0.13
Current Ratio
3.86
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-03-31 | 0.13 |
| 2025-09-30 | 0.44 |
| 2025-03-31 | 0.48 |
| 2024-09-30 | 0.44 |
| 2024-03-31 | 0.49 |
| 2023-09-30 | 0.00 |
